People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2017 |
| Zavante Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $1.6B | 2015 |
| Trius Therapeutics Inc | — | Biotechnology | Series B | $49.3M | $1.2B | 2011 |
| Incline Therapeutics, Inc. | — | Biotechnology | Series B | $43.9M | $853.3M | 2010 |
Theodore R. Schroeder at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Theodore R. Schroeder on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Stein | 2 | 4 |
| James Topper | 1 | 12 |
| Cam L. Garner | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Risa Stack | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| David Kabakoff | 1 | 7 |
| Terry Gould | 1 | 6 |
| John Finn | 1 | 5 |
| Jim Young | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Steve Elms | 1 | 4 |
| Scott M. Rocklage | 1 | 4 |
| John Schmid | 1 | 4 |
| Jim Glasheen | 1 | 3 |
| Alan Levy, Ph.D. | 1 | 3 |
| Paul Truex | 1 | 3 |
| Daniel D. Burgess | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.